Toggle Main Menu Toggle Search

Open Access padlockePrints

Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer

Lookup NU author(s): Dr Jennifer Munkley, Professor Craig Robson, Professor Hing Leung, Dr Prabhakar Rajan, Professor David Elliott



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


BackgroundAndrogens drive the onset and progression of prostate cancer (PCa) via androgen receptor (AR) signalling. The principal treatment for PCa is androgen deprivation therapy, although the majority of patients eventually develop a lethal castrate-resistant form of the disease, where despite low serum testosterone levels AR signalling persists. Advanced PCa often has hyper-activated RAS/ERK1/2 signalling thought to be due to loss of function of key negative regulators of the pathway, the details of which are not fully understood.MethodsWe recently carried out a genome-wide study and identified a subset of 226 novel androgen-regulated genes (PLOS ONE 6:e29088, 2011). In this study we have meta-analysed this dataset with genes and pathways frequently mutated in PCa to identify androgen-responsive regulators of the RAS/ERK1/2 pathway.ResultsWe find the PTGER4 and TSPYL2 genes are up-regulated by androgen stimulation and the ADCY1, OPKR1, TRIB1, SPRY1 and PTPRR are down-regulated by androgens. Further characterisation of PTPRR protein in LNCaP cells revealed it is an early and direct target of the androgen receptor which negatively regulates the RAS/ERK1/2 pathway and reduces cell proliferation in response to androgens.ConclusionOur data suggest that loss of PTPRR in clinical PCa is one factor that might contribute to activation of the RAS/ERK1/2 pathway.

Publication metadata

Author(s): Munkley J, Lafferty NP, Kalna G, Robson CN, Leung HY, Rajan P, Elliott DJ

Publication type: Article

Publication status: Published

Journal: BMC Cancer

Year: 2015

Volume: 15

Print publication date: 16/01/2015

Online publication date: 16/01/2015

Acceptance date: 06/01/2015

Date deposited: 30/04/2015

ISSN (electronic): 1471-2407

Publisher: BioMed Central


DOI: 10.1186/s12885-015-1012-8


Altmetrics provided by Altmetric


Funder referenceFunder name
J. G. W Patterson Foundation, Cancer Research UK
Prostate Cancer UK
WT080368MAWellcome Trust
WT089225/Z/09/ZWellcome Trust
089225/Z/09/ZWellcome Trust